Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN)
· seekingalpha.com
Biohaven faces challenges following a partial clinical hold on its lead asset, opakalim, and ongoing high cash burn. Read more on BHVN stock here.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...